IL-23R-CAR-Treg cell therapy (Sangamo Therapeutics)

N/A

Report date: 2025/03/20 16:02:53

Base Information

Drug NameIL-23R-CAR-Treg cell therapy (Sangamo Therapeutics)

Drug Alias NameCAR Tregs targeting IL23R (Sangamo Therapeutics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin 23 Receptor modulators

TargetsInterleukin 23 Receptor

Therapy Area/IndicationsCrohn Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSangamo Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCrohn Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A